JP2007520450A - 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法 - Google Patents

非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法 Download PDF

Info

Publication number
JP2007520450A
JP2007520450A JP2006533951A JP2006533951A JP2007520450A JP 2007520450 A JP2007520450 A JP 2007520450A JP 2006533951 A JP2006533951 A JP 2006533951A JP 2006533951 A JP2006533951 A JP 2006533951A JP 2007520450 A JP2007520450 A JP 2007520450A
Authority
JP
Japan
Prior art keywords
cell
maytansinoid
ester
antibody
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520450A5 (US07989598-20110802-C00010.png
Inventor
スティーブス，リタ
ルッツ，ロバート
チャリ，ラヴィ
シェ，ホンシェン
コフトゥン，イェレナ
Original Assignee
イミュノジェン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34467962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007520450(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イミュノジェン・インコーポレーテッド filed Critical イミュノジェン・インコーポレーテッド
Publication of JP2007520450A publication Critical patent/JP2007520450A/ja
Publication of JP2007520450A5 publication Critical patent/JP2007520450A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
JP2006533951A 2003-10-10 2004-10-12 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法 Pending JP2007520450A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50990103P 2003-10-10 2003-10-10
US10/960,602 US8088387B2 (en) 2003-10-10 2004-10-08 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PCT/US2004/030917 WO2005037992A2 (en) 2003-10-10 2004-10-12 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011148625A Division JP5718745B2 (ja) 2003-10-10 2011-07-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法

Publications (2)

Publication Number Publication Date
JP2007520450A true JP2007520450A (ja) 2007-07-26
JP2007520450A5 JP2007520450A5 (US07989598-20110802-C00010.png) 2011-01-27

Family

ID=34467962

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2006533951A Pending JP2007520450A (ja) 2003-10-10 2004-10-12 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2011148625A Active JP5718745B2 (ja) 2003-10-10 2011-07-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2014078553A Active JP5926759B2 (ja) 2003-10-10 2014-04-07 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2016021695A Pending JP2016135786A (ja) 2003-10-10 2016-02-08 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2017114877A Withdrawn JP2017200934A (ja) 2003-10-10 2017-06-12 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2018187555A Pending JP2019011363A (ja) 2003-10-10 2018-10-02 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2019038151A Pending JP2019142864A (ja) 2003-10-10 2019-03-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2020132965A Withdrawn JP2020189854A (ja) 2003-10-10 2020-08-05 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2022023780A Withdrawn JP2022068295A (ja) 2003-10-10 2022-02-18 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2024025206A Pending JP2024059792A (ja) 2003-10-10 2024-02-22 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法

Family Applications After (9)

Application Number Title Priority Date Filing Date
JP2011148625A Active JP5718745B2 (ja) 2003-10-10 2011-07-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2014078553A Active JP5926759B2 (ja) 2003-10-10 2014-04-07 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2016021695A Pending JP2016135786A (ja) 2003-10-10 2016-02-08 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2017114877A Withdrawn JP2017200934A (ja) 2003-10-10 2017-06-12 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2018187555A Pending JP2019011363A (ja) 2003-10-10 2018-10-02 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2019038151A Pending JP2019142864A (ja) 2003-10-10 2019-03-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2020132965A Withdrawn JP2020189854A (ja) 2003-10-10 2020-08-05 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2022023780A Withdrawn JP2022068295A (ja) 2003-10-10 2022-02-18 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2024025206A Pending JP2024059792A (ja) 2003-10-10 2024-02-22 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法

Country Status (25)

Country Link
US (10) US8088387B2 (US07989598-20110802-C00010.png)
EP (4) EP2612682A3 (US07989598-20110802-C00010.png)
JP (10) JP2007520450A (US07989598-20110802-C00010.png)
KR (4) KR101343676B1 (US07989598-20110802-C00010.png)
CN (3) CN107198778A (US07989598-20110802-C00010.png)
AU (2) AU2004282491C1 (US07989598-20110802-C00010.png)
BE (1) BE2013C075I2 (US07989598-20110802-C00010.png)
BR (1) BRPI0415448A8 (US07989598-20110802-C00010.png)
CA (3) CA2542128C (US07989598-20110802-C00010.png)
CY (2) CY1113984T1 (US07989598-20110802-C00010.png)
DK (1) DK1689846T3 (US07989598-20110802-C00010.png)
EA (1) EA010508B1 (US07989598-20110802-C00010.png)
EC (1) ECSP066461A (US07989598-20110802-C00010.png)
ES (1) ES2404304T3 (US07989598-20110802-C00010.png)
HK (1) HK1244452A1 (US07989598-20110802-C00010.png)
HR (1) HRP20130412T1 (US07989598-20110802-C00010.png)
HU (1) HUS1300075I1 (US07989598-20110802-C00010.png)
IL (4) IL173625A (US07989598-20110802-C00010.png)
LU (1) LU92336I2 (US07989598-20110802-C00010.png)
NO (2) NO337458B1 (US07989598-20110802-C00010.png)
NZ (2) NZ583844A (US07989598-20110802-C00010.png)
PL (1) PL1689846T3 (US07989598-20110802-C00010.png)
PT (1) PT1689846E (US07989598-20110802-C00010.png)
SI (1) SI1689846T1 (US07989598-20110802-C00010.png)
WO (1) WO2005037992A2 (US07989598-20110802-C00010.png)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504585A (ja) * 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
JP2013506709A (ja) * 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
JP2013544253A (ja) * 2010-11-17 2013-12-12 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP2016106222A (ja) * 2009-10-26 2016-06-16 ネステク ソシエテ アノニム 抗ｔｎｆ薬及び自己抗体の検出用アッセイ
JP2016518332A (ja) * 2013-03-13 2016-06-23 ノバルティス アーゲー 抗体薬物コンジュゲート
WO2019150985A1 (ja) * 2018-01-31 2019-08-08 国立大学法人東京大学 抗体薬物複合体及びそれを含む医薬組成物

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP1718667B1 (en) * 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
KR101200133B1 (ko) * 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
AU2006213662B2 (en) * 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
CN101222926B (zh) * 2005-04-15 2013-07-17 默沙东公司 用于治疗或预防癌症的方法和组合物
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
BRPI0615049B1 (pt) 2005-08-24 2023-04-25 Immunogen, Inc Processo para a preparação de um conjugado de anticorpo- maitansinóide
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
KR101459160B1 (ko) 2006-01-20 2014-11-19 제넨테크, 인크. 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
BRPI0711249A2 (pt) 2006-05-30 2012-03-13 Genentech, Inc. Anticorpos, polinucleotídeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar câncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fabricação
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
ES2381788T3 (es) 2007-07-16 2012-05-31 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
WO2009012256A1 (en) * 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
EP3858347A3 (en) 2007-08-17 2021-12-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
IL287292B (en) 2008-01-31 2022-09-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
UA127472C2 (uk) 2008-03-18 2023-09-06 Дженентек, Інк. Комбінація кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичного засобу і спосіб застосування
SI2281006T1 (sl) * 2008-04-30 2017-12-29 Immunogen, Inc. Premreževalci in njihova uporaba
BRPI0911442A2 (pt) * 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
WO2009134870A1 (en) * 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
US20100092495A1 (en) * 2008-04-30 2010-04-15 Immunogen Inc. Potent cell-binding agent drug conjugates
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
EP3100745B1 (en) 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
HUE061117T2 (hu) 2009-03-25 2023-05-28 Genentech Inc Anti-FGFR3 antitestek és eljárások alkalmazásukra
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
WO2010126979A1 (en) 2009-04-29 2010-11-04 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
DK2437790T3 (da) 2009-06-03 2019-05-20 Immunogen Inc Konjugeringsfremgangsmåder
ES2537566T3 (es) 2009-06-04 2015-06-09 Novartis Ag Métodos para identificación de sitios para conjugación de IgG
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
PL2516465T3 (pl) 2009-12-23 2016-11-30 Przeciwciała anty-bv8 i ich zastosowania
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
AU2011221226A1 (en) * 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20220017432A (ko) 2010-02-24 2022-02-11 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
TWI586806B (zh) 2010-04-23 2017-06-11 建南德克公司 異多聚體蛋白質之製造
CN103119442A (zh) 2010-06-03 2013-05-22 霍夫曼-拉罗奇有限公司 抗体和免疫偶联物的免疫peg成像及其用途
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
MX2013004761A (es) 2010-10-29 2013-08-27 Immunogen Inc Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
CN105399831A (zh) * 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
PT2668209T (pt) 2011-01-24 2021-04-07 Gilead Sciences Inc Anticorpos seletivos para células que apresentam egfr em alta densidade
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
EP2670776B1 (en) 2011-02-04 2018-11-21 F. Hoffmann-La Roche AG Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
MY183977A (en) 2011-02-15 2021-03-17 Immunogen Inc Cytotoxic benzodiazepine derivatives
EA025786B1 (ru) * 2011-03-29 2017-01-30 Иммуноджен, Инк. Способ производства конъюгатов с улучшенной гомогенностью
US8795673B2 (en) 2011-03-29 2014-08-05 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
MX346555B (es) 2011-04-01 2017-03-24 Immunogen Inc Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
JP6018622B2 (ja) 2011-04-01 2016-11-02 イミュノジェン， インコーポレイテッド Ｃｄ３７結合性分子及びその免疫複合体
JP2014513692A (ja) 2011-05-09 2014-06-05 ユニバーシティ オブ バージニア パテント ファウンデーション 癌を治療するための組成物及び方法
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
KR101972303B1 (ko) 2011-06-10 2019-04-25 메르사나 테라퓨틱스, 인코포레이티드 단백질-중합체-약물 접합체
SG195172A1 (en) 2011-06-21 2013-12-30 Immunogen Inc Novel maytansinoid derivatives with peptide linker and conjugates thereof
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
JO3625B1 (ar) 2011-09-22 2020-08-27 Amgen Inc بروتينات رابطة للأنتيجين cd27l
US9364551B2 (en) 2011-09-29 2016-06-14 Virginia Commonwealth University Light-enabled drug delivery
MX2014004991A (es) 2011-10-28 2014-05-22 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma.
CN104168922A (zh) 2011-11-16 2014-11-26 安姆根有限公司 治疗表皮生长因子缺失突变体viii相关疾病的方法
EP2794010A4 (en) 2011-11-21 2015-10-21 Immunogen Inc METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE
MX358680B (es) 2011-12-08 2018-08-31 Biotest Ag Usos de inmunoconjugados dirigidos a cd138.
ES2710916T3 (es) 2011-12-22 2019-04-29 I2 Pharmaceuticals Inc Proteínas de unión sustitutas
US9717803B2 (en) * 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
JP2015505537A (ja) 2012-01-20 2015-02-23 シー レーン バイオテクノロジーズ， エルエルシー 結合分子コンジュゲート
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
WO2013150623A1 (ja) 2012-04-04 2013-10-10 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３（ｐ－カドヘリン）抗体の薬剤コンジュゲート
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CN104540518A (zh) 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
EP2844300B1 (en) 2012-05-01 2018-10-17 Genentech, Inc. Anti-pmel17 antibodies and immunoconjugates
JP6423340B2 (ja) 2012-05-15 2018-11-14 シアトル ジェネティクス，インコーポレイティド 自己安定化リンカー結合体
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
JP6239597B2 (ja) * 2012-05-15 2017-11-29 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 薬物コンジュゲート、コンジュゲーション方法およびその使用
BR112014028366A2 (pt) 2012-05-21 2017-06-27 Genentech Inc anticorpos anti-ly6e e imunoconjugados e métodos de uso
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
CN104797270A (zh) 2012-08-02 2015-07-22 基因泰克公司 抗etbr抗体和免疫偶联物
CA2879665A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
PL3486248T3 (pl) 2012-09-26 2021-10-25 Immunogen, Inc. Ulepszone sposoby acylacji majtansynolu
CN105209592A (zh) 2012-10-04 2015-12-30 伊缪诺金公司 使用pvdf膜纯化细胞结合剂细胞毒性剂缀合物
MX2015006109A (es) 2012-11-15 2016-02-05 Endocyte Inc Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
CN103333246B (zh) * 2012-12-21 2015-09-16 百奥泰生物科技(广州)有限公司 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
CN104688740A (zh) * 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6494533B2 (ja) 2013-02-28 2019-04-03 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP2970474B1 (en) 2013-03-14 2017-12-20 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
JP6847388B2 (ja) 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス，インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
EP2968590B1 (en) * 2013-03-15 2018-09-05 Novartis AG Antibody drug conjugates
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105658240A (zh) * 2013-06-04 2016-06-08 西托姆克斯治疗公司 用于缀合可活化抗体的组合物和方法
US10071170B2 (en) 2013-06-24 2018-09-11 Ablbio Antibody-drug conjugate having improved stability and use thereof
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
CA2915897A1 (en) 2013-07-05 2015-01-08 Formation Biologics Inc. Egfr antibody conjugates
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
RU2560699C2 (ru) * 2013-08-02 2015-08-20 федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) Способ создания наноразмерной диагностической метки на основе конъюгатов наночастиц и однодоменных антител
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
EP3038624A1 (en) 2013-08-26 2016-07-06 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
SG10201913351XA (en) 2013-09-05 2020-03-30 Jackson Lab Compositions for rna-chromatin interaction analysis and uses thereof
KR102298172B1 (ko) 2013-09-06 2021-09-06 아카데미아 시니카 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
CA2922889A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
SG11201602361UA (en) 2013-10-08 2016-04-28 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
ES2754397T3 (es) 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
MX367851B (es) 2013-10-11 2019-09-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco.
CA2921707C (en) 2013-10-15 2023-03-28 Seattle Genetics, Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
EP3057610B1 (en) 2013-10-15 2021-09-22 Sorrento Therapeutics, Inc. Drug-conjugates with a targeting molecule and two different drugs
RS65324B1 (sr) 2013-10-18 2024-04-30 Novartis Ag Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate
AU2014340378A1 (en) 2013-10-21 2016-04-21 Genentech, Inc. Anti-Ly6E antibodies and methods of use
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US10273303B2 (en) 2013-11-13 2019-04-30 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
CA2931356A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
TWI777502B (zh) 2013-12-19 2022-09-11 美商西雅圖遺傳學公司 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
WO2015108203A1 (ja) 2014-01-15 2015-07-23 株式会社オーダーメードメディカルリサーチ 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106459055B (zh) 2014-01-27 2019-11-01 辉瑞大药厂 双功能细胞毒类药剂
WO2015113476A1 (zh) 2014-01-29 2015-08-06 上海恒瑞医药有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
EP4190809A1 (en) 2014-02-11 2023-06-07 Seagen Inc. Selective reduction of proteins
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
BR112016024462B1 (pt) 2014-05-06 2022-12-27 Genentech, Inc Métodos para a preparação de um anticorpo
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN107074945B (zh) 2014-05-27 2021-08-24 中央研究院 增进抗体功效的通用糖型的组合物及方法
WO2015184002A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
JP6602834B2 (ja) * 2014-06-30 2019-11-06 ターベダ セラピューティクス インコーポレイテッド 標的化コンジュゲートならびにその粒子及び製剤
DK3160513T3 (da) 2014-06-30 2020-04-06 Glykos Finland Oy Saccharidderivat af en toksisk payload og antistofkonjugater deraf
EP3164420A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
MA42561A (fr) 2014-09-02 2018-04-25 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicament
EA034138B1 (ru) 2014-09-03 2020-01-09 Иммуноджен, Инк. Цитотоксические бензодиазепиновые производные
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
IL285102B2 (en) 2014-09-11 2024-06-01 Seagen Inc Targeted administration of medicinal substances containing a tertiary amine
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
WO2016059377A1 (en) 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
UY36401A (es) 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
JP6872482B2 (ja) 2014-11-27 2021-05-19 ザイムワークス，インコーポレイテッド Ｈｅｒ２を標的とする二重特異性抗原結合性構築物の使用方法
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
CN114656483A (zh) 2014-12-04 2022-06-24 细胞基因公司 生物分子共轭物
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
EP4137159A1 (en) 2015-01-28 2023-02-22 Sorrento Therapeutics, Inc. Antibody drug conjugates
WO2016151432A1 (en) 2015-03-20 2016-09-29 Pfizer Inc. Bifunctional cytotoxic agents containing the cti pharmacophore
KR102668727B1 (ko) 2015-04-24 2024-05-28 제넨테크, 인크. 다중특이적 항원-결합 단백질
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
MX2017015039A (es) 2015-06-08 2018-08-09 Debiopharm Int Sa Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20.
JP6802840B2 (ja) * 2015-06-09 2020-12-23 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド 抗体薬物複合体、中間体、その製造方法、薬学的組成物及び応用
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
LT3313845T (lt) 2015-06-29 2020-12-10 Immunogen, Inc. Cisteino inžinerijos antikūnų konjugatai
CA2988591A1 (en) * 2015-06-30 2017-01-05 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN108026103B (zh) 2015-07-21 2021-04-16 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
WO2017025458A1 (en) 2015-08-07 2017-02-16 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
CA2995243A1 (en) 2015-08-28 2017-03-09 Debiopharm International, S.A. Antibodies and assays for detection of cd37
EP3347049B1 (en) * 2015-09-08 2024-07-03 Waters Technologies Corporation Multidimensional chromatography method for analysis of antibody-drug conjugates
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
CN116396393A (zh) 2015-10-08 2023-07-07 酵活英属哥伦比亚省公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
WO2017075495A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
US20170189548A1 (en) 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2017211120C1 (en) 2016-01-25 2021-10-07 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
CA3013412C (en) 2016-02-04 2023-10-10 Suzhou M-Conj Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
TW201808343A (zh) 2016-08-09 2018-03-16 美商西雅圖遺傳學公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
US9950070B2 (en) * 2016-08-16 2018-04-24 Korea University Research And Business Foundation HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
BR112019006778A2 (pt) 2016-10-18 2019-10-15 Seattle Genetics Inc Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco
AU2017345454A1 (en) 2016-10-19 2019-05-30 Invenra Inc. Antibody constructs
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
KR102459469B1 (ko) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CN110392685B (zh) 2016-11-23 2023-07-04 伊缪诺金公司 苯并二氮卓衍生物的选择性磺化
CN110382534B (zh) 2016-11-29 2023-05-09 里珍纳龙药品有限公司 治疗prlr阳性乳腺癌的方法
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
MX2019007019A (es) 2016-12-22 2019-08-16 Univ Degli Studi Magna Graecia Catanzaro Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
ES2912266T3 (es) 2016-12-23 2022-05-25 Immunogen Inc Inmunoconjugados dirigidos a ADAM9 y procedimientos de uso de los mismos
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
WO2018160539A1 (en) 2017-02-28 2018-09-07 Immunogen, Inc. Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
KR20190141181A (ko) 2017-04-27 2019-12-23 시애틀 지네틱스, 인크. 사차화된 니코틴아미드 아데닌 다이뉴클레오타이드 구제 경로 억제제 콘쥬게이트
US20180311375A1 (en) * 2017-04-27 2018-11-01 Cadila Healthcare Limited Process of preparing antibody-drug conjugate
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
RU2019142330A (ru) 2017-06-30 2021-07-30 Займворкс, Инк. Стабилизированные химерные fab
JP7241080B2 (ja) 2017-08-28 2023-03-16 アンジーエックス・インコーポレーテッド 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
TW202344272A (zh) 2018-04-13 2023-11-16 美商建南德克公司 穩定抗cd79b免疫結合物調配物
CN113227127A (zh) 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
SG11202012257VA (en) 2018-06-26 2021-01-28 Immunogen Inc Immunoconjugates targeting adam9 and methods of use thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
AU2019311077A1 (en) 2018-07-23 2021-02-25 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
AU2019311557A1 (en) 2018-07-25 2021-02-04 Daiichi Sankyo Company, Limited Effective method for manufacturing antibody-drug conjugate
CN112512591A (zh) 2018-09-26 2021-03-16 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020187998A1 (en) 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
CA3134055A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
MA55520A (fr) 2019-03-29 2022-02-09 Immunogen Inc Dérivés de bis-benzodiazépine cytotoxiques et leurs conjugués avec des agents de liaison à une cellule pour inhiber la croissance cellulaire anormale ou pour traiter des maladies prolifératives
MX2021012961A (es) 2019-04-24 2021-11-25 Heidelberg Pharma Res Gmbh Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
KR20220027828A (ko) 2019-04-26 2022-03-08 이뮤노젠 아이엔씨 캄프토테신 유도체
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
WO2021052402A1 (zh) 2019-09-18 2021-03-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
WO2021060439A1 (ja) 2019-09-26 2021-04-01 日油株式会社 ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
TW202140078A (zh) 2020-01-22 2021-11-01 大陸商上海森輝醫藥有限公司 艾日布林衍生物的藥物偶聯物、其製備方法及其在醫藥上的應用
WO2021173773A1 (en) 2020-02-25 2021-09-02 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
CN111195353B (zh) * 2020-03-19 2023-06-23 烟台迈百瑞国际生物医药股份有限公司 一种美登素类抗体药物偶联物及其应用
MX2022011769A (es) 2020-03-25 2022-10-18 Jiangsu Hengrui Pharmaceuticals Co Ltd Metodo de preparacion de medicamento de conjugado de anticuerpo.
JP2023518583A (ja) 2020-03-25 2023-05-02 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体を含む医薬組成物及びその使用 本願は、２０２０年３月２５日に提出された中国特許出願（出願番号ｃｎ ２０２０１０２１９６０１．７）及び２０２１年３月１７日に提出された中国特許出願（出願番号ｃｎ ２０２１１０２８７０１２．７）の優先権を主張する。
US20230173093A1 (en) 2020-04-10 2023-06-08 Seagen Inc. Charge variant linkers
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
CA3238167A1 (en) 2021-11-19 2023-05-25 Maria Leia Smith Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2024023735A1 (en) 2022-07-27 2024-02-01 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161490A (ja) * 1989-10-25 1991-07-11 Immunogen Inc メイタンシノイドを含む細胞障害剤及び該細胞障害剤を有効成分とする医薬
WO2003057163A2 (en) * 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
WO2003068956A1 (en) * 2002-02-13 2003-08-21 Xoma Technology Ltd. Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
WO2003074081A1 (en) * 2002-02-28 2003-09-12 Mindset Biopharmaceuticals Usa Inc. SPECIFIC ANTIBODIES TO AMYLOID β PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
GB1603640A (en) 1977-07-20 1981-11-25 Gist Brocades Nv Enzyme particles
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS58167592A (ja) 1982-03-26 1983-10-03 Takeda Chem Ind Ltd 新規メイタンシノイド化合物
LU86212A1 (fr) 1985-12-16 1987-07-24 Omnichem Sa Nouveaux conjugues de la vinblastine et de ses derives,procede pour leur preparation et compositions pharmaceutiques les contenant
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
JPS6484959A (en) 1987-09-25 1989-03-30 Nec Corp System for connecting test line
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
FR2656555B1 (fr) * 1989-12-29 1994-10-28 Serimer Systeme mecanique de guidage automatique d'une ou plusieurs torches d'une unite de soudage a l'arc.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
ES2129454T3 (es) 1991-08-22 1999-06-16 Becton Dickinson Co Procedimientos y composiciones de tratamientos de cancer y pronostico de reacciones a los indicados tratamientos.
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US7754211B2 (en) 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
JP2861631B2 (ja) 1992-05-06 1999-02-24 日本電気株式会社 Ｆｓｋ受信機
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
EP1231274A3 (en) 1994-11-21 2002-10-09 The University Of Leeds Modified porteinase inhibitors
US5679648A (en) 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US5614692A (en) 1995-06-30 1997-03-25 Tracor Aerospace, Inc. Shaped-charge device with progressive inward collapsing jet
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
EP0840770A4 (en) 1996-05-23 2002-03-20 Ian Alexander Gilmour PROCESS FOR THE EXTRACTION OF PROANTHOCYANIDINES FROM BOTANICAL SUBSTANCES
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
AU4330097A (en) 1996-08-30 1998-03-19 Eli Lilly And Company Pharmaceutical compounds
JPH1084959A (ja) * 1996-09-06 1998-04-07 Nobuyoshi Shimizu 細胞表面レセプターに対するモノクローナル抗体ならびにそのフラグメントの結合体ならびに複合体、それらの製法ならびに細胞への嵌入方法および使用方法
EP0937083B1 (en) * 1996-09-20 2003-04-23 Meiji Seika Kaisha Ltd. A crystalline substance of cefditoren pivoxil and the production of the same
AU4982097A (en) 1996-10-18 1998-05-15 Board Of Regents, The University Of Texas System Anti-erbb2 antibodies
EP1460083B1 (en) 1996-11-06 2006-01-18 Sequenom, Inc. Analysing method and apparatus
CA2274641A1 (en) 1996-12-12 1998-06-18 David Richard Corbin Improved packaging composition
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK1027437T3 (da) 1997-10-29 2008-11-24 Genentech Inc Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO2002016429A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
AU5963699A (en) 1998-10-02 2000-04-26 Mcmaster University Spliced form of (erb)b-2/neu oncogene
AU770952B2 (en) 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis
DK1169021T3 (da) 1999-04-01 2010-01-11 Hana Biosciences Inc Sammensætninger og fremgangsmåder til behandling af lymfom
KR100816572B1 (ko) 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
EP1637160A3 (en) 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
WO2000069638A1 (en) 1999-05-12 2000-11-23 Array Ab Direct printing device with cleaning unit
CA2374085C (en) 1999-05-14 2015-12-29 Genentech, Inc. Tumour treatment with anti-erbb2 antibodies
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
CN100482281C (zh) * 1999-06-25 2009-04-29 基因技术股份有限公司 抗ErbB抗体-类美坦素偶联物在制备药物中的应用
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN100381172C (zh) 1999-06-25 2008-04-16 吉尼泰克公司 使用抗-ErbB2抗体治疗前列腺癌
AU784045B2 (en) 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
JP2003528805A (ja) 1999-07-12 2003-09-30 ジェネンテック・インコーポレーテッド Ｃｄ２０に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
BE1012928A6 (nl) 1999-10-07 2001-06-05 Hoeberigs Jean Marie Mathieu Cilinderoven voor verwarming van frites met hete lucht.
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
CN1413220A (zh) 1999-10-29 2003-04-23 杰南技术公司 抗前列腺干细胞抗原(psca)抗体组合物及其应用方法
DE60032633T2 (de) 1999-11-24 2007-10-04 Immunogen Inc., Cambridge Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung
PL356966A1 (en) * 2000-02-11 2004-07-12 Eli Lilly And Company Selective n-acylation of a82846 glycopeptide analogs
WO2001062300A2 (en) 2000-02-24 2001-08-30 Genentech, Inc. Caspase activated prodrugs therapy
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
AU2001283740A1 (en) 2000-08-17 2002-02-25 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
ATE457318T1 (de) 2000-12-28 2010-02-15 Kyowa Hakko Kirin Co Ltd Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP2000545B1 (en) 2001-06-20 2011-08-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of lung tumor
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20080085283A1 (en) 2001-09-05 2008-04-10 Levinson Arthur D Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
JP5224632B2 (ja) * 2001-09-05 2013-07-03 ジェネンテック， インコーポレイテッド 細胞増殖異常に伴う疾患に関連するポリペプチド抗原の同定方法及びそのような疾患の治療に有効な組成物
US20030109682A1 (en) * 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
WO2005063299A2 (en) 2003-12-24 2005-07-14 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
US6913748B2 (en) * 2002-08-16 2005-07-05 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
AU2003259913A1 (en) 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EA009285B1 (ru) * 2003-05-14 2007-12-28 Иммуноджен, Инк. Композиция конъюгированного лекарственного средства
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
JP2007503202A (ja) 2003-07-21 2007-02-22 イミュノジェン・インコーポレーテッド Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法
US7754441B2 (en) 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
JP3991983B2 (ja) 2003-12-19 2007-10-17 日産自動車株式会社 車両の駆動制御装置
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PT2135881E (pt) 2005-06-20 2011-12-21 Genentech Inc Anticorpos que se ligam ao antigénio tat10772 associado a tumor para o diagnóstico e tratamento de tumor
US7195520B1 (en) 2006-07-18 2007-03-27 Chung-Chuan Huang Connector for antenna
UA127472C2 (uk) 2008-03-18 2023-09-06 Дженентек, Інк. Комбінація кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичного засобу і спосіб застосування
SI2281006T1 (sl) * 2008-04-30 2017-12-29 Immunogen, Inc. Premreževalci in njihova uporaba
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
BR112013014316A2 (pt) 2010-12-09 2016-09-27 Genentech Inc tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161490A (ja) * 1989-10-25 1991-07-11 Immunogen Inc メイタンシノイドを含む細胞障害剤及び該細胞障害剤を有効成分とする医薬
WO2003057163A2 (en) * 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
WO2003068956A1 (en) * 2002-02-13 2003-08-21 Xoma Technology Ltd. Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
WO2003074081A1 (en) * 2002-02-28 2003-09-12 Mindset Biopharmaceuticals Usa Inc. SPECIFIC ANTIBODIES TO AMYLOID β PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504585A (ja) * 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
JP2016056209A (ja) * 2009-09-09 2016-04-21 セントローズ， エルエルシー 細胞外標的化薬物複合体
JP2013506709A (ja) * 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
JP2016106222A (ja) * 2009-10-26 2016-06-16 ネステク ソシエテ アノニム 抗ｔｎｆ薬及び自己抗体の検出用アッセイ
JP2013544253A (ja) * 2010-11-17 2013-12-12 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP2016518332A (ja) * 2013-03-13 2016-06-23 ノバルティス アーゲー 抗体薬物コンジュゲート
WO2019150985A1 (ja) * 2018-01-31 2019-08-08 国立大学法人東京大学 抗体薬物複合体及びそれを含む医薬組成物

Also Published As

Publication number Publication date
ES2404304T3 (es) 2013-05-27
CN108578710B (zh) 2021-11-19
AU2004282491C1 (en) 2011-06-30
EP2596804A3 (en) 2013-09-18
KR20130102649A (ko) 2013-09-17
CY2014002I2 (el) 2020-05-29
AU2010212291C1 (en) 2012-11-29
KR101343676B1 (ko) 2013-12-20
US20170226220A1 (en) 2017-08-10
CN107198778A (zh) 2017-09-26
NO337458B1 (no) 2016-04-18
NO20061772L (no) 2006-04-21
EP2596804A2 (en) 2013-05-29
ECSP066461A (es) 2007-05-30
AU2004282491B2 (en) 2010-12-23
IL246605A (en) 2017-08-31
WO2005037992A3 (en) 2009-04-23
US8198417B2 (en) 2012-06-12
CA3237922A1 (en) 2005-04-28
JP2017200934A (ja) 2017-11-09
IL173625A0 (en) 2006-07-05
US20120226025A1 (en) 2012-09-06
HK1244452A1 (zh) 2018-08-10
US20080114153A1 (en) 2008-05-15
BRPI0415448A8 (pt) 2019-08-13
US20140154804A1 (en) 2014-06-05
JP2024059792A (ja) 2024-05-01
WO2005037992A2 (en) 2005-04-28
IL214788A0 (en) 2011-11-30
AU2004282491A1 (en) 2005-04-28
SI1689846T1 (en) 2013-06-28
JP2019011363A (ja) 2019-01-24
US20050169933A1 (en) 2005-08-04
CA3139478A1 (en) 2005-04-28
JP2019142864A (ja) 2019-08-29
JP2014177463A (ja) 2014-09-25
CN103223174A (zh) 2013-07-31
DK1689846T3 (da) 2013-05-06
IL173625A (en) 2016-07-31
BE2013C075I2 (US07989598-20110802-C00010.png) 2023-12-18
US8088387B2 (en) 2012-01-03
CN108578710A (zh) 2018-09-28
NZ583844A (en) 2011-06-30
EA200600752A1 (ru) 2007-08-31
LU92336I2 (fr) 2014-02-17
EP1689846A4 (en) 2010-08-04
JP2012006928A (ja) 2012-01-12
CY1113984T1 (el) 2016-07-27
EP2596803A2 (en) 2013-05-29
KR101573124B1 (ko) 2015-12-01
EP2596803A3 (en) 2013-09-11
AU2010212291B2 (en) 2012-05-24
EP1689846A2 (en) 2006-08-16
NO2016001I2 (no) 2016-01-26
PT1689846E (pt) 2013-05-08
JP2020189854A (ja) 2020-11-26
PL1689846T3 (pl) 2013-07-31
US8685920B2 (en) 2014-04-01
US20080145374A1 (en) 2008-06-19
HUS1300075I1 (hu) 2014-02-28
CA2542128C (en) 2022-01-11
NZ545195A (en) 2010-07-30
AU2010212291A1 (en) 2010-09-02
US7989598B2 (en) 2011-08-02
US20080171865A1 (en) 2008-07-17
JP5926759B2 (ja) 2016-05-25
US20110281856A1 (en) 2011-11-17
US20210261683A1 (en) 2021-08-26
JP2016135786A (ja) 2016-07-28
HRP20130412T1 (en) 2013-06-30
EP2612682A3 (en) 2013-09-25
CA2542128A1 (en) 2005-04-28
US8563509B2 (en) 2013-10-22
NO2016001I1 (no) 2016-01-26
BRPI0415448A (pt) 2006-12-05
US10844135B2 (en) 2020-11-24
KR101476082B1 (ko) 2014-12-23
JP2022068295A (ja) 2022-05-09
IL235253B (en) 2018-04-30
EP1689846B1 (en) 2013-03-27
KR20060130552A (ko) 2006-12-19
US20080171856A1 (en) 2008-07-17
LU92336I9 (US07989598-20110802-C00010.png) 2019-01-16
KR20120034800A (ko) 2012-04-12
JP5718745B2 (ja) 2015-05-13
US8163888B2 (en) 2012-04-24
KR20140033003A (ko) 2014-03-17
EA010508B1 (ru) 2008-10-30
CY2014002I1 (el) 2020-05-29
EP2612682A2 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
US20210261683A1 (en) Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110330

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110705

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120806